Literature DB >> 22946513

Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week.

Katherine A Barraclough1, Christine E Staatz, David W Johnson, Katie J Lee, Brett C McWhinney, Jacobus Pj Ungerer, Carmel M Hawley, Scott B Campbell, Diana R Leary, Nicole M Isbel.   

Abstract

This study analysed associations between tacrolimus, mycophenolic acid (MPA) and prednisolone exposures on day 4 and month 1 post kidney transplant and clinical outcomes. Area under the concentration-time curve (AUC) for each drug was estimated using validated multiple regression-derived limited sampling strategies. Multivariate logistic regression was used to associate drug exposure with clinical outcomes. One hundred and twenty subjects were studied. Between-subject variability in dose-adjusted exposure to each medication was high. Both day 4 tacrolimus and MPA exposures were independently predictive of delayed graft function (2.6 change in odds for a standard deviation (SD) increase in tacrolimus AUC(0-12) , P = 0.02; 0.23 change in odds for a SD increase in MPA AUC(0-12) , P = 0.02). Both day 4 MPA and total prednisolone exposures were independently predictive of rejection (0.20 change in odds for a SD increase in MPA AUC(0-12) , P = 0.04; 0.40 change in odds for a SD increase in total prednisolone AUC(0-6) , P = 0.03). Lowest tertile exposure to all three immunosuppressant medications imposed significantly higher odds of rejection [adjusted odds ratio 34.2 (95% CI 4.1, 284.4), P = 0.001]. This study highlights the importance of achieving early target exposure and suggests a potential role for individualized initial dosing or early therapeutic monitoring of all three immunosuppressive agents.
© 2012 The Authors. Transplant International © 2012 European Society for Organ Transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22946513     DOI: 10.1111/j.1432-2277.2012.01553.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  11 in total

1.  Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis.

Authors:  Azrin N Abd Rahman; Susan E Tett; Halim A Abdul Gafor; Brett C McWhinney; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

2.  Patterns in Tacrolimus Variability and Association with De Novo Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients.

Authors:  Kim H Piburn; Vaka K Sigurjonsdottir; Olafur S Indridason; Lynn Maestretti; Mary Victoria Patton; Anne McGrath; Runolfur Palsson; Amy Gallo; Abanti Chaudhuri; Paul C Grimm
Journal:  Clin J Am Soc Nephrol       Date:  2022-07-26       Impact factor: 10.614

3.  Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients.

Authors:  Troels K Bergmann; Nicole M Isbel; Remo Ostini; Katherine A Barraclough; Scott B Campbell; Brett C McWhinney; Warrick J Inder; Anthony Russell; Christine E Staatz
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

4.  Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population.

Authors:  Shwetal Lalan; Susan Abdel-Rahman; Andrea Gaedigk; J Steven Leeder; Bradley A Warady; Hongying Dai; Douglas Blowey
Journal:  Pediatr Nephrol       Date:  2014-05-30       Impact factor: 3.714

Review 5.  A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation.

Authors:  Jessica E Ericson; Kanecia O Zimmerman; Daniel Gonzalez; Chiara Melloni; Jeffrey T Guptill; Kevin D Hill; Huali Wu; Michael Cohen-Wolkowiez
Journal:  Ther Drug Monit       Date:  2017-02       Impact factor: 3.118

6.  Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.

Authors:  Anders Åsberg; Karsten Midtvedt; Mike van Guilder; Elisabet Størset; Sara Bremer; Stein Bergan; Roger Jelliffe; Anders Hartmann; Michael N Neely
Journal:  Transpl Int       Date:  2013-10-15       Impact factor: 3.782

7.  Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients.

Authors:  Jun Zhang; Zhi Sun; Zhenfeng Zhu; Jing Yang; Jian Kang; Guiwen Feng; Lin Zhou; Lihua Zuo; Yonggang Luo; Xiaojian Zhang
Journal:  Front Pharmacol       Date:  2018-08-13       Impact factor: 5.810

Review 8.  Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention.

Authors:  David K Metz; Nick Holford; Joshua Y Kausman; Amanda Walker; Noel Cranswick; Christine E Staatz; Katherine A Barraclough; Francesco Ierino
Journal:  Transplantation       Date:  2019-10       Impact factor: 4.939

Review 9.  Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients.

Authors:  Amelia R Cossart; Nicole M Isbel; Carla Scuderi; Scott B Campbell; Christine E Staatz
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

10.  Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C0 and AUC.

Authors:  Aurelija Radzevičienė; Edgaras Stankevičius; Franck Saint-Marcoux; Pierre Marquet; Rima Maslauskienë; Edmundas Kaduševičius
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.